Cargando…

Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease

Acute graft-versus-host disease (GvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), a potentially curative treatment for leukemia. Endoplasmic reticulum (ER) stress occurs when the protein folding capacity of the ER is oversaturated. How ER stress m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haring, Eileen, Andrieux, Geoffroy, Uhl, Franziska M., Krausz, Máté, Proietti, Michele, Sauer, Barbara, Esser, Philipp R., Martin, Stefan F., Pfeifer, Dietmar, Schmitt-Graeff, Annette, Duyster, Justus, Köhler, Natalie, Grimbacher, Bodo, Boerries, Melanie, Aumann, Konrad, Zeiser, Robert, Apostolova, Petya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article - Cell Therapy and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244832/ https://www.ncbi.nlm.nih.gov/pubmed/34407601 http://dx.doi.org/10.3324/haematol.2021.278387

Ejemplares similares

Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect
por: Haring, Eileen, et al.
Publicado: (2020)

Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease
por: Haring, Eileen, et al.
Publicado: (2021)

The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease
por: Apostolova, Petya, et al.
Publicado: (2016)

Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation
por: Waterhouse, Miguel, et al.
Publicado: (2022)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

Dysregulated PI3K Signaling in B Cells of CVID Patients
por: Harder, Ina, et al.
Publicado: (2022)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation
por: Stickel, Natalie, et al.
Publicado: (2017)

Altered Spectrum of Lymphoid Neoplasms in a Single-Center Cohort of Common Variable Immunodeficiency with Immune Dysregulation
por: Wehr, Claudia, et al.
Publicado: (2021)

IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma
por: Balakrishnan, Ilango, et al.
Publicado: (2022)

CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
por: Bozorgmehr, Najmeh, et al.
Publicado: (2023)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
por: Berger, Susanna Carolina, et al.
Publicado: (2022)

Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 co-stimulation
por: Vaidya, Abishek, et al.
Publicado: (2022)

Therapeutic potential of fetal liver cell transplantation in hemophilia A mice
por: Merlin, Simone, et al.
Publicado: (2023)

Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation
por: Tassi, Elena, et al.
Publicado: (2022)

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
por: Asherie, Nathalie, et al.
Publicado: (2022)

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
por: Vasileiou, Spyridoula, et al.
Publicado: (2022)

Intestinal IgA-positive plasma cells are highly sensitive indicators of alloreaction early after allogeneic transplantation and associate with both graft-versus-host disease and relapse-related mortality
por: Scheidler, Lucia, et al.
Publicado: (2023)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation
por: Heinz, Amadeus T., et al.
Publicado: (2023)

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
por: Song, Zhiqiang, et al.
Publicado: (2023)

Alteration of Proteotranscriptomic Landscape Reveals the Transcriptional Regulatory Circuits Controlling Key-Signaling Pathways and Metabolic Reprogramming During Tumor Evolution
por: Andrieux, Geoffroy, et al.
Publicado: (2020)

“Immune TOR-opathies,” a Novel Disease Entity in Clinical Immunology
por: Jung, Sophie, et al.
Publicado: (2018)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dsabg2tramhosuu1us0r98ct3m